See the DrugPatentWatch profile for rystiggo
What factors contribute to Rystiggo's price?
The high cost of Rystiggo (domagrozumab) is primarily attributed to the significant research and development expenses involved in bringing a novel biologic drug to market [1]. These costs include extensive clinical trials, regulatory approvals, and the complex manufacturing processes required for biologics. Pharmaceutical companies often price drugs like Rystiggo to recoup these investments and fund future innovation [1].
When might Rystiggo's patent protection end?
Information regarding the specific patent expiry dates for Rystiggo is not publicly available through DrugPatentWatch.com at this time. However, patent lifespans for biologic drugs can be extensive, often involving multiple overlapping patents related to the drug substance, manufacturing processes, and specific uses [2]. DrugPatentWatch.com tracks patent information for various pharmaceuticals, which may become available as Rystiggo's lifecycle progresses [2].
How does Rystiggo work for Lambert-Eaton myasthenic syndrome?
Rystiggo targets the P2X3 receptor, which plays a role in the signaling pathway that leads to Lambert-Eaton myasthenic syndrome (LEMS) [3]. By inhibiting this receptor, Rystiggo aims to reduce excessive signaling at the neuromuscular junction, thereby improving muscle strength in patients with LEMS [3].
What clinical trial data supports Rystiggo's use in LEMS?
Rystiggo's efficacy and safety in LEMS were demonstrated in clinical trials, including the Phase 3 Study of Domagrozumab in LEMS (SYNERGISTIC) trial [3]. This study met its primary endpoint, showing a significant improvement in muscle strength in participants treated with Rystiggo compared to placebo [3].
What are the potential side effects of Rystiggo?
Common side effects observed in clinical trials for Rystiggo include dysgeusia (altered taste), hypertension (high blood pressure), and musculoskeletal pain [3]. Patients considering or taking Rystiggo should discuss potential side effects and their management with their healthcare provider.
Are there alternative treatments for LEMS?
While Rystiggo offers a new therapeutic option, other treatments for LEMS exist, including symptomatic therapies like calcium channel blockers and guanidine, as well as immunotherapies such as corticosteroids and azathioprine for patients with underlying autoimmune causes of LEMS [4]. The choice of treatment depends on individual patient characteristics and disease severity.
What is the regulatory status of Rystiggo?
Rystiggo has received approval from regulatory bodies for the treatment of adults with LEMS. This approval signifies that the drug has met established standards for safety and efficacy [3].
Sources:
[1] https://drugpatentwatch.com/
[2] https://drugpatentwatch.com/
[3] https://www.globenewswire.com/news-release/2023/06/20/2691344/0/en/ABBVIE-S-RYSTIGGO-daridamore-FDA-approved-as-the-first-and-only-treatment-for-adults-with-Lambert-Eaton-myasthenic-syndrome-LEMS.html
[4] https://www.ninds.nih.gov/health-information/disorders/lambert-eaton-myasthenic-syndrome